TipRanks
Dianthus Therapeutics (DE:87E)
XETRA:87E
Germany Market

Dianthus Therapeutics (87E) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

87E Analyst Ratings

Strong Buy
13Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Dianthus
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

87E Stock 12 Month Forecast

Average Price Target

€126.84
▲(40.94% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Dianthus Therapeutics in the last 3 months. The average price target is €126.84 with a high forecast of €177.63 and a low forecast of €108.35. The average price target represents a 40.94% change from the last price of €90.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"28":"€28","103":"€103","178":"€178","65.5":"€65.5","140.5":"€140.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":177.630148,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€177.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":126.84407386727275,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€126.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":108.35439028,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€108.35</span>\n  </div></div>","useHTML":true}}],"tickPositions":[28,65.5,103,140.5,178],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.5,87.04847292307693,94.59694584615384,102.14541876923077,109.69389169230769,117.24236461538462,124.79083753846155,132.33931046153845,139.88778338461537,147.4362563076923,154.98472923076923,162.53320215384616,170.0816750769231,{"y":177.630148,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.5,83.14185183594405,86.78370367188812,90.42555550783217,94.06740734377624,97.70925917972029,101.35111101566434,104.99296285160841,108.63481468755246,112.27666652349652,115.91851835944058,119.56037019538464,123.20222203132869,{"y":126.84407386727275,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.5,81.71956848307693,83.93913696615385,86.15870544923077,88.37827393230769,90.59784241538462,92.81741089846155,95.03697938153846,97.25654786461538,99.47611634769231,101.69568483076924,103.91525331384616,106.13482179692309,{"y":108.35439028,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.5,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€177.63Average Price Target€126.84Lowest Price Target€108.35
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:87E
H.C. Wainwright
H.C. Wainwright
€140.33
Buy
55.92%
Upside
Reiterated
10/01/26
H.C. Wainwright Reaffirms Their Buy Rating on Dianthus Therapeutics (DNTH)
LifeSci Capital Analyst forecast on DE:87E
LifeSci Capital
LifeSci Capital
€111.02
Buy
23.35%
Upside
Reiterated
09/29/26
Dianthus Reaffirmed at Buy as Claseprubart Data Strengthen Neuromuscular Outlook; Price Target Maintained at $125
J.P. Morgan Analyst forecast on DE:87E
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
09/24/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
William Blair Analyst forecast on DE:87E
William Blair
William Blair
―
Buy
―
Reiterated
09/18/26
Analyst Reiterates Buy on Dianthus as Claseprubart Data Momentum and New Pipeline Assets Strengthen Risk-Reward Profile
Citi
€138.55
Buy
53.95%
Upside
Initiated
09/04/26
Dianthus initiated with a Buy at CitiDianthus initiated with a Buy at Citi
Stifel Nicolaus Analyst forecast on DE:87E
Stifel Nicolaus
Stifel Nicolaus
€118.12
Buy
31.25%
Upside
Reiterated
08/13/26
Dianthus Therapeutics (DNTH) Receives a Rating Update from a Top Analyst
Evercore ISI
€119.01
Buy
32.24%
Upside
Reiterated
08/10/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (NYSE: HIMS) and Dianthus Therapeutics (NASDAQ: DNTH)
Truist Financial Analyst forecast on DE:87E
Truist Financial
Truist Financial
€97.7→€113.68
Buy
26.31%
Upside
Reiterated
08/06/26
Dianthus Therapeutics (DNTH) Gets a Buy from Truist Financial
TD Cowen Analyst forecast on DE:87E
TD Cowen
TD Cowen
€133.22
Buy
48.03%
Upside
Assigned
08/05/26
Analysts Conflicted on These Healthcare Names: Dianthus Therapeutics (NASDAQ: DNTH) and American Well (NYSE: AMWL)
Guggenheim Analyst forecast on DE:87E
Guggenheim
Guggenheim
€177.63
Buy
97.37%
Upside
Reiterated
08/05/26
Analysts Are Bullish on These Healthcare Stocks: Dianthus Therapeutics (DNTH), Nyxoah (NYXH)
Wedbush
€93.26→€108.35
Buy
20.39%
Upside
Reiterated
08/05/26
Wedbush Reaffirms Their Buy Rating on Dianthus Therapeutics (DNTH)
Clear Street Analyst forecast on DE:87E
Clear Street
Clear Street
€115.46
Buy
28.29%
Upside
Reiterated
08/05/26
Analysts Are Bullish on Top Healthcare Stocks: Alphatec Holdings (ATEC), Tyra Bioscience (TYRA)
Wells Fargo Analyst forecast on DE:87E
Wells Fargo
Wells Fargo
€119.9
Buy
33.22%
Upside
Reiterated
08/05/26
Wells Fargo Sticks to Their Buy Rating for Dianthus Therapeutics (DNTH)
Jefferies
€117.24
Buy
30.26%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Medpace Holdings (NASDAQ: MEDP)
Raymond James Analyst forecast on DE:87E
Raymond James
Raymond James
―
Buy
―
Reiterated
06/12/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:87E
H.C. Wainwright
H.C. Wainwright
€140.33
Buy
55.92%
Upside
Reiterated
10/01/26
H.C. Wainwright Reaffirms Their Buy Rating on Dianthus Therapeutics (DNTH)
LifeSci Capital Analyst forecast on DE:87E
LifeSci Capital
LifeSci Capital
€111.02
Buy
23.35%
Upside
Reiterated
09/29/26
Dianthus Reaffirmed at Buy as Claseprubart Data Strengthen Neuromuscular Outlook; Price Target Maintained at $125
J.P. Morgan Analyst forecast on DE:87E
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
09/24/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
William Blair Analyst forecast on DE:87E
William Blair
William Blair
―
Buy
―
Reiterated
09/18/26
Analyst Reiterates Buy on Dianthus as Claseprubart Data Momentum and New Pipeline Assets Strengthen Risk-Reward Profile
Citi
€138.55
Buy
53.95%
Upside
Initiated
09/04/26
Dianthus initiated with a Buy at CitiDianthus initiated with a Buy at Citi
Stifel Nicolaus Analyst forecast on DE:87E
Stifel Nicolaus
Stifel Nicolaus
€118.12
Buy
31.25%
Upside
Reiterated
08/13/26
Dianthus Therapeutics (DNTH) Receives a Rating Update from a Top Analyst
Evercore ISI
€119.01
Buy
32.24%
Upside
Reiterated
08/10/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (NYSE: HIMS) and Dianthus Therapeutics (NASDAQ: DNTH)
Truist Financial Analyst forecast on DE:87E
Truist Financial
Truist Financial
€97.7→€113.68
Buy
26.31%
Upside
Reiterated
08/06/26
Dianthus Therapeutics (DNTH) Gets a Buy from Truist Financial
TD Cowen Analyst forecast on DE:87E
TD Cowen
TD Cowen
€133.22
Buy
48.03%
Upside
Assigned
08/05/26
Analysts Conflicted on These Healthcare Names: Dianthus Therapeutics (NASDAQ: DNTH) and American Well (NYSE: AMWL)
Guggenheim Analyst forecast on DE:87E
Guggenheim
Guggenheim
€177.63
Buy
97.37%
Upside
Reiterated
08/05/26
Analysts Are Bullish on These Healthcare Stocks: Dianthus Therapeutics (DNTH), Nyxoah (NYXH)
Wedbush
€93.26→€108.35
Buy
20.39%
Upside
Reiterated
08/05/26
Wedbush Reaffirms Their Buy Rating on Dianthus Therapeutics (DNTH)
Clear Street Analyst forecast on DE:87E
Clear Street
Clear Street
€115.46
Buy
28.29%
Upside
Reiterated
08/05/26
Analysts Are Bullish on Top Healthcare Stocks: Alphatec Holdings (ATEC), Tyra Bioscience (TYRA)
Wells Fargo Analyst forecast on DE:87E
Wells Fargo
Wells Fargo
€119.9
Buy
33.22%
Upside
Reiterated
08/05/26
Wells Fargo Sticks to Their Buy Rating for Dianthus Therapeutics (DNTH)
Jefferies
€117.24
Buy
30.26%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Medpace Holdings (NASDAQ: MEDP)
Raymond James Analyst forecast on DE:87E
Raymond James
Raymond James
―
Buy
―
Reiterated
06/12/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ZVRAZevra Therapeutics
DFTXDefinium Therapeutics
HITIHigh Tide
DNLIDenali Therapeutics
MDWDMediwound
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dianthus Therapeutics

3 Months
Success Rate
7/8 ratings generated profit
88%
Average Return
+48.08%
Copying Gavin Clark-Gartner's trades and holding each position for 3 Months would result in 87.50% of your transactions generating a profit, with an average return of +48.08% per trade.
1 Year
Success Rate
7/8 ratings generated profit
88%
Average Return
+177.56%
Copying Gavin Clark-Gartner's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +177.56% per trade.
2 Years
Success Rate
13/14 ratings generated profit
93%
Average Return
+158.93%
Copying Laura Chico's trades and holding each position for 2 Years would result in 92.86% of your transactions generating a profit, with an average return of +158.93% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

87E Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
8
7
7
1
2
Buy
17
16
19
17
16
Hold
1
1
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
26
24
26
18
18
In the current month, 87E has received 18 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 87E average Analyst price target in the past 3 months is 126.84.
Each month's total comprises the sum of three months' worth of ratings.

87E Financial Forecast

87E Earnings Forecast

Next quarter’s earnings estimate for 87E is -€0.83 with a range of -€1.00 to -€0.35. The previous quarter’s EPS was -€0.79. 87E beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 87E has Performed in-line its overall industry.
Next quarter’s earnings estimate for 87E is -€0.83 with a range of -€1.00 to -€0.35. The previous quarter’s EPS was -€0.79. 87E beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 87E has Performed in-line its overall industry.

87E Sales Forecast

Next quarter’s sales forecast for 87E is €391.95K with a range of €0.00 to €882.78K. The previous quarter’s sales results were €671.80K. 87E beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 87E has Performed in-line its overall industry.
Next quarter’s sales forecast for 87E is €391.95K with a range of €0.00 to €882.78K. The previous quarter’s sales results were €671.80K. 87E beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 87E has Performed in-line its overall industry.

87E Stock Forecast FAQ

What is DE:87E’s average 12-month price target, according to analysts?
Based on analyst ratings, Dianthus Therapeutics’s 12-month average price target is 126.84.
    What is DE:87E’s upside potential, based on the analysts’ average price target?
    Dianthus Therapeutics has 40.94% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Dianthus Therapeutics a Buy, Sell or Hold?
          Dianthus Therapeutics has a consensus rating of Strong Buy, which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Dianthus Therapeutics’s share price target?
            The average share price target for Dianthus Therapeutics is 126.84. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €177.63 ,and the lowest forecast is €108.35. The average share price target represents 40.94% Increase from the current price of €90.
              What do analysts say about Dianthus Therapeutics?
              Dianthus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of Dianthus Therapeutics?
                To buy shares of DE:87E, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.